tirzepatide for the treatment of obstructive sleep apnea and obesity Original Article: (SURMOUNT-OSA) buff.ly/4ccuPKO Editorial: Entering a New Era in Sleep-Apnea Treatment buff.ly/3XyX1D2 Sleep Apnea Reduced in People

Using this assay, about 5.4% of all genotypes 1 were not classified at the subtype level in our centre 14

Response: We thank the commenters for their feedback on these issues, including the importance of antimicrobial stewardship

Melena in dogs is black, tarry, sticky stool caused by digested blood

At 24 weeks, retatrutide 12 mg delivers 17.5% body weight loss versus an estimated 12-13% for tirzepatide 15 mg

But, before starting any new type of exercise, please consult with your physician first

After 6 months of therapy, those taking GLP1 drugs showed: Elevated risk of androgenic alopecia Elevated risk of nonscarring hair loss No significant change in telogen effluvium risk No significant change in alopecia areata risk At the 12-month mark, the pattern had shifted slightly: Continued higher risk for androgenic alopecia Continued higher risk for nonscarring hair loss A newly increased risk of telogen effluvium Still no change in risk of alopecia areata The apparent absence of a link between GLP1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association